Multiple myeloma remains an incurable malignancy of plasma cells. Novel therapies, notably proteasome inhibitors and immunomodulatory drugs, have improved the survival of multiple myeloma patients; however, patients either present with, or develop resistance to, these therapies. Resistance to traditional chemotherapeutic agents can be caused by cellular drug efflux via adenosine triphosphate (ATP)-binding cassette (ABC) transporters, but it is still not clear whether these transporters mediate resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma. Solute carrier (SLC) transporters also play a role in cancer drug resistance due to changes in cell homeostasis caused by their abnormal expression and changes in the solutes they transport. In this review, we evaluate resistance to novel therapies used to treat multiple myeloma, as mediated by drug and solute transporters.

中文翻译：

---

药物和溶质转运蛋白介导多发性骨髓瘤对新疗法的耐药性

多发性骨髓瘤仍然是一种无法治愈的浆细胞恶性肿瘤。新疗法，尤其是蛋白酶体抑制剂和免疫调节药物，提高了多发性骨髓瘤患者的生存率；然而，患者要么出现，要么对这些疗法产生抗药性。细胞药物通过三磷酸腺苷 (ATP) 结合盒 (ABC) 转运蛋白流出可引起对传统化疗药物的耐药性，但尚不清楚这些转运蛋白是否介导多发性骨髓瘤对蛋白酶体抑制剂和免疫调节药物的耐药性。溶质载体 (SLC) 转运蛋白也在抗癌药物中发挥作用，这是因为它们的异常表达和它们转运的溶质的变化引起的细胞稳态变化。在本次审查中，